Sarepta Therapeutics (SRPT) Vyondys 53 Granted Accelerated FDA Approval to Treat DMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Sarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse
December 13, 2019 7:44 AM ESTCredit Suisse analyst Martin Auster raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $185.00) while maintaining an Outperform rating after the FDA approved Vyondys 53.
The company plans to price the drug at parity with Exondys 51 or >$600,000 for a... MoreSarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
December 13, 2019 6:19 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining an Outperform rating following approval of Vyondys 53/golodirsen.
The analyst commented, "We view tonight's approval of Vyondys 53/golodirsen as a significant win for SRPT,... More
Sarepta Therapeutics (SRPT) halted, news pending
December 12, 2019 5:52 PM ESTSarepta Therapeutics (NASDAQ: SRPT) halted, news pending
... More